Clinics operating medical aesthetics, longevity membership, or wellness-adjacent programs are increasingly asked by patients about Wharton's jelly allografts and exosome preparations. This page is written for the clinic evaluating whether and how to add these categories to a program, not for a patient audience. It does not describe any product as anti-aging, rejuvenating, or corrective of any condition. It describes what the products are, what documentation a buyer should request, and where the regulatory line sits today.
Why this category draws extra scrutiny
Aesthetic and longevity marketing has a long history of overstating what a biologic product does, and FDA has responded accordingly. Recent warning letters to distributors in this space cite website and social media language that implied disease treatment or cosmetic correction as the basis for enforcement, not the underlying tissue or vesicle product itself.
A clinic adding Wharton's jelly or exosome products to a longevity or aesthetic menu should assume that every public-facing claim about the product, not just clinical documentation, is read by regulators as evidence of intended use. That includes website copy, consult scripts, and social posts produced by the clinic itself.
We supply tissue and vesicle products with documentation. We do not supply, review, or approve clinic marketing language, and we do not make representations about what a product will do for a patient's appearance or aging process.
- Public-facing claims (website, social, consult materials) are treated by regulators as evidence of intended use
- Distributor and clinic marketing are both in scope, not just clinical use
- A buyer's internal compliance review should cover its own patient-facing materials, independent of supplier documentation
Wharton's jelly products in an aesthetic or longevity context
Wharton's jelly allografts are a matrix recovered from donated umbilical cord tissue, supplied under the 361 HCT/P framework described in 21 CFR 1271.10. Whether a specific intended use in a given clinic qualifies under that framework, including minimal manipulation and homologous use, is a determination for the clinic and its own regulatory counsel, not something a distributor can certify on the clinic's behalf.
These products are not labeled or supplied as stem cell therapies. Independent analyses of commercial cord tissue allografts have found low viable cell counts and have not documented reliable populations of colony-forming mesenchymal stromal cells, so a 'stem cell' label is not supported by the available documentation for this product category.
For a longevity or aesthetic program, the relevant procurement questions are the same ones that apply to any clinical category: what is the certificate of analysis for the lot, what donor eligibility and sterility testing was performed, and how will the clinic track the product to the patient record.
- Framework: 361 HCT/P, with homologous use and minimal manipulation assessed by the clinic's own counsel
- Documentation available to verified accounts: certificate of analysis, donor eligibility summary, lot release record
- Not supplied or labeled as a stem cell product
Exosome products: a different regulatory posture
Extracellular vesicle and exosome products, including cord blood-derived preparations, sit outside the 361 pathway. FDA has stated publicly that there are no FDA-approved exosome products, and these products are generally regulated as biologic drugs under section 351 of the Public Health Service Act.
That distinction matters more in an aesthetic or longevity setting because patient-facing marketing in this category tends to drift toward appearance or performance language. A clinic considering an exosome product for any program should route the purchase and use decision through its own regulatory and legal counsel before it reaches a patient-facing offering.
Analytical characterization (particle concentration, marker identification, growth factor and cytokine panels reported by the supplier) describes what has been measured in the product. It is not a description of what the product does when used, and we do not present it that way.
- No FDA-approved exosome products exist as of this writing, per FDA's public statement
- Exosome products are generally regulated as biologic drugs under section 351, not as 361 HCT/Ps
- Analytical panels (NTA, ELISA, SP-IRIS, marker and growth factor data) are reported as measurements, not effects
What to request before adding either category to a program
Clinics building out a longevity or aesthetic offering should treat the procurement review the same way an orthopedic or pain practice would: documentation first, marketing language second, and the marketing review done internally against current FDA warning letter trends.
Account verification for either product family requires an NPI number. Pricing is not published and is available to verified accounts directly.
We are available for physician-level conversations about product documentation, processing descriptions, and testing records. We do not advise on clinical use, dosing, protocols, or how a product should be positioned to patients.
- Request the certificate of analysis and donor eligibility summary for the specific lot before purchase
- Confirm cold chain or shelf-stable handling requirements match your storage capability
- Review your own patient-facing materials against current FDA warning letter language before launch, independent of supplier claims
Frequently asked questions
Can we market Wharton's jelly or exosome products as anti-aging or skin rejuvenation treatments?+
We do not make those claims about any product and cannot advise on clinic marketing. Recent FDA warning letters in this category were based substantially on website and social media claims, so a clinic should have its own compliance review of any patient-facing language before using it.
Are exosome products available for aesthetic or longevity use the same way Wharton's jelly products are?+
They are a different regulatory category. FDA has stated there are no FDA-approved exosome products, and they are generally treated as biologic drugs under section 351 rather than the 361 framework that applies to Wharton's jelly allografts. The purchase and use decision belongs to the physician and their counsel.
Do you certify that a given use in our aesthetic program qualifies as homologous use under 21 CFR 1271.10?+
No. Whether a specific intended use meets minimal manipulation and homologous use requirements is a determination for the clinic and its regulatory counsel, based on how the clinic intends to use the product.
What documentation can we request before adding a product to our program?+
Verified accounts can request the certificate of analysis, donor eligibility summary, and lot release record for a given lot, along with supplier-reported characterization data for exosome products. Full ingredient disclosures are available where applicable.